

1. REFERENCES

1. Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. *J Infect.* 2010;60(6):474-7.
2. Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K, Williams A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. *AIDS.* 2009;23(9):1.
3. Parker BJ, Wannemuehler KA, Marston BJ, N.P. G, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS.* 2009;23(4):5.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach [Guideline]. Geneva, Switzerland 2016 [updated June. Available from: <https://www.who.int/hiv/pub/arv/arv-2016/en/>.
5. Coetzee LM, Cassim N, Glencross DK, editors. Rapid scale up of reflexed Cryptococcal antigen (CrAg) screening across a CD4 laboratory network in South Africa. International Aids Society (IAS); 2017 23-26 July; Paris, France.
6. Mokone G, Mojalefa S, Coetzee L, Glencross DK, editors. Implementation of a National Cryptococcal antigen (CrAg) reflexed screening programme in South Africa. Society of Medical Laboratory Science of South Africa (SMLTSA); 2017 19-21 May 2017; Durban, South Africa.
7. Cassim N, Coetzee LM, Govender NP, Glencross DK. District and sub-district analysis of cryptococcal antigenaemia prevalence and specimen positivity in KwaZulu-Natal, South Africa. *Afr J Lab Med.* 2018;7(1):757.
8. Coetzee LM, Cassim N, Sriruttan C, Mhlana M, Govender NP, Glencross DK. Cryptococcal antigen positivity combined with the percentage of HIV-seropositive samples with CD4 counts <100 cells/mul identifies districts in South Africa with advanced burden of disease. *PLoS One.* 2018;13(6):e0198993.
9. Govender NP, Glencross DK. National coverage of reflex cryptococcal antigen screening: A milestone achievement in the care of persons with advanced HIV disease. *S Afr Med J.* 2018;108(7):534-5.
10. Greene G, Lawrence DS, Jordan A, Chiller T, Jarvis JN. Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa. *Expert Rev Anti Infect Ther.* 2020:1-12.
11. Cassim N, Coetzee LM, Schnippel K, Glencross DK. Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals. *PLoS One.* 2017;12(8):e0182154.
12. Cassim N, Schnippel K, Coetzee LM, Glencross DK. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/mul using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa. *PLoS One.* 2017;12(2):e0171675.
13. Blasich NP, Coetzee LM, Sriruttan C, DeSanto D, Greene GS, Glencross DK, et al. Retrospective Assessment of a National Reflex Cryptococcal Antigen Screening Program in South Africa Through Interlaboratory Comparison of Lateral Flow Assay Results. *Lab Med.* 2022.
14. Kozel TR, Bauman SK. CrAg lateral flow assay for cryptococcosis. *Expert Opin Med Diagn.* 2012;6(3):245-51.
15. Li Z, Wang M, Zeng P, Chen Z, Zhan Y, Li S, et al. Examination of a Chinese-made cryptococcal glucuronoxylomannan antigen test in serum and bronchoalveolar lavage fluid for diagnosing pulmonary cryptococcosis in HIV-negative patients. *J Microbiol Immunol Infect.* 2022;55(2):307-13.
16. Tadeo KK, Nimwesiga A, Kwizera R, Apeduno L, Martyn E, Okirwoth M, et al. Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis. *J Clin Microbiol.* 2021;59(8):e0086021.
17. Noguera MC, Escandon P, Rodriguez J, Parody A, Camargo L. Comparison of two commercial tests (Immy vs. Dynamiker) for cryptococcal capsular antigen. *Rev Soc Bras Med Trop.* 2021;54:e03072021.
18. Kwizera R, Omali D, Tadeo K, Kasibante J, Rutakingirwa MK, Kagimu E, et al. Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis. *J Clin Microbiol.* 2021;59(3).
19. Tenforde MW, Boyer-Chammard T, Muthoga C, Tawe L, Milton T, Rulaganyang I, et al. Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. *J Clin Microbiol.* 2020;59(1).
20. Skipper C, Tadeo K, Martyn E, Nalintya E, Rajasingham R, Meya DB, et al. Evaluation of Serum Cryptococcal Antigen Testing Using Two Novel Semiquantitative Lateral Flow Assays in Persons with Cryptococcal Antigenemia. *J Clin Microbiol.* 2020;58(4).
21. Jarvis JN, Tenforde MW, Lechiile K, Milton T, Boose A, Leeme TB, et al. Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. *J Clin Microbiol.* 2020;58(9).
22. (WHO) WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Guideline. Geneva, Switzerland; 2018 March.
23. Govender NP, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. *Southern African Journal of HIV Medicine; Vol 20, No 1 (2019)DO - 104102/sajhivmedv20i11030.* 2019.